- Home
- URGN vs GAIN Comparison
URGN vs GAIN Comparison
Compare URGN & GAIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- GAIN
- Stock Information
- Founded
- URGN 2004
- GAIN 2005
- Country
- URGN United States
- GAIN United States
- Employees
- URGN N/A
- GAIN N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- GAIN Finance: Consumer Services
- Sector
- URGN Health Care
- GAIN Finance
- Exchange
- URGN Nasdaq
- GAIN Nasdaq
- Market Cap
- URGN 547.1M
- GAIN 473.7M
- IPO Year
- URGN 2017
- GAIN 2005
- Fundamental
- Price
- URGN $11.33
- GAIN $13.14
- Analyst Decision
- URGN Strong Buy
- GAIN Hold
- Analyst Count
- URGN 5
- GAIN 2
- Target Price
- URGN $44.50
- GAIN $13.75
- AVG Volume (30 Days)
- URGN 351.4K
- GAIN 118.8K
- Earning Date
- URGN 11-06-2024
- GAIN 02-04-2025
- Dividend Yield
- URGN N/A
- GAIN 7.30%
- EPS Growth
- URGN N/A
- GAIN N/A
- EPS
- URGN N/A
- GAIN 1.06
- Revenue
- URGN $89,363,000.00
- GAIN $91,472,000.00
- Revenue This Year
- URGN $13.39
- GAIN $5.77
- Revenue Next Year
- URGN $45.06
- GAIN $3.37
- P/E Ratio
- URGN N/A
- GAIN $12.40
- Revenue Growth
- URGN 15.64
- GAIN 11.51
- 52 Week Low
- URGN $10.60
- GAIN $12.46
- 52 Week High
- URGN $20.70
- GAIN $14.96
- Technical
- Relative Strength Index (RSI)
- URGN 37.97
- GAIN 35.22
- Support Level
- URGN $11.10
- GAIN $13.46
- Resistance Level
- URGN $13.13
- GAIN $13.92
- Average True Range (ATR)
- URGN 0.53
- GAIN 0.22
- MACD
- URGN -0.10
- GAIN -0.04
- Stochastic Oscillator
- URGN 12.15
- GAIN 8.24
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About GAIN Gladstone Investment Corporation Business Development Company
Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to (i) achieve and grow current income by investing in debt securities of established businesses. (ii) provide our stockholders with long-term capital appreciation in the value of our assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.